fexagratinib (ABSK091)

News alerts, weekly reports and conference planners

Company:

Abbisko, AstraZeneca

Drug class:

FGFR inhibitor

Related drugs:

FGFR1 amplification	Gastric Cancer	FGFR1 amplification	Gastric Cancer	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2
FGFR2 amplification	Gastroesophageal Cancer	FGFR2 amplification	Gastroesophageal Cancer	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	durvalumab + ABSK091 Sensitive: C3 – Early Trials durvalumab + ABSK091 Sensitive : C3	durvalumab + ABSK091 Sensitive: C3 – Early Trials durvalumab + ABSK091 Sensitive : C3
TMB-H	Urothelial Cancer	TMB-H	Urothelial Cancer	durvalumab + ABSK091 Sensitive: C3 – Early Trials durvalumab + ABSK091 Sensitive : C3	durvalumab + ABSK091 Sensitive: C3 – Early Trials durvalumab + ABSK091 Sensitive : C3
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
TMB-H	Urothelial Cancer	TMB-H	Urothelial Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
FGFR3-TACC3 F17T8	Urothelial Cancer	FGFR3-TACC3 F17T8	Urothelial Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
FGFR2 Y376C	Cholangiocarcinoma	FGFR2 Y376C	Cholangiocarcinoma	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
FGFR3-TACC3 F17T8	Cervical Cancer	FGFR3-TACC3 F17T8	Cervical Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
FGFR3 A393E	Urothelial Cancer	FGFR3 A393E	Urothelial Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
FGFR1 amplification	HER2 Negative Breast Cancer	FGFR1 amplification	HER2 Negative Breast Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
EGFR mutation	Solid Tumor	EGFR mutation	Solid Tumor	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
EGFR amplification	Solid Tumor	EGFR amplification	Solid Tumor	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
EGFR fusion	Solid Tumor	EGFR fusion	Solid Tumor	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
BAG4-FGFR1 B2F6	Salivary Gland Cancer	BAG4-FGFR1 B2F6	Salivary Gland Cancer	ABSK091 Sensitive: C4 – Case Studies ABSK091 Sensitive : C4	ABSK091 Sensitive: C4 – Case Studies ABSK091 Sensitive : C4
BRCA2 exon 11 deletion	Cervical Cancer	BRCA2 exon 11 deletion	Cervical Cancer	ABSK091 Sensitive: C4 – Case Studies ABSK091 Sensitive : C4	ABSK091 Sensitive: C4 – Case Studies ABSK091 Sensitive : C4
FGFR3-TACC3 fusion	Astrocytoma	FGFR3-TACC3 fusion	Astrocytoma	ABSK091 Sensitive: C4 – Case Studies ABSK091 Sensitive : C4	ABSK091 Sensitive: C4 – Case Studies ABSK091 Sensitive : C4
TERT promoter mutation	Renal Cell Carcinoma	TERT promoter mutation	Renal Cell Carcinoma	ABSK091 Sensitive: C4 – Case Studies ABSK091 Sensitive : C4	ABSK091 Sensitive: C4 – Case Studies ABSK091 Sensitive : C4
FGFR2 A391E	Urothelial Cancer	FGFR2 A391E	Urothelial Cancer	ABSK091 Sensitive: C4 – Case Studies ABSK091 Sensitive : C4	ABSK091 Sensitive: C4 – Case Studies ABSK091 Sensitive : C4
FGFR3 V555M	Multiple Myeloma	FGFR3 V555M	Multiple Myeloma	ABSK091 Resistant: D – Preclinical ABSK091 Resistant : D	ABSK091 Resistant: D – Preclinical ABSK091 Resistant : D
FGFR3 S249C	Urothelial Cancer	FGFR3 S249C	Urothelial Cancer	ABSK091 Sensitive: D – Preclinical ABSK091 Sensitive : D	ABSK091 Sensitive: D – Preclinical ABSK091 Sensitive : D
FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	ABSK091 Sensitive: D – Preclinical ABSK091 Sensitive : D	ABSK091 Sensitive: D – Preclinical ABSK091 Sensitive : D
FGFR1 V561M	Non Small Cell Lung Cancer	FGFR1 V561M	Non Small Cell Lung Cancer	ABSK091 Resistant: D – Preclinical ABSK091 Resistant : D	ABSK091 Resistant: D – Preclinical ABSK091 Resistant : D
FGFR1 mutation	Squamous Cell Carcinoma of Head and Neck	FGFR1 mutation	Squamous Cell Carcinoma of Head and Neck	ABSK091 + AZD2014 Sensitive: D – Preclinical ABSK091 + AZD2014 Sensitive : D	ABSK091 + AZD2014 Sensitive: D – Preclinical ABSK091 + AZD2014 Sensitive : D
NRAS G13N	Multiple Myeloma	NRAS G13N	Multiple Myeloma	ABSK091 Resistant: D – Preclinical ABSK091 Resistant : D	ABSK091 Resistant: D – Preclinical ABSK091 Resistant : D
FGFR1 amplification	Lung Cancer	FGFR1 amplification	Lung Cancer	ABSK091 + NBL-001 + BI2536 Sensitive: D – Preclinical ABSK091 + NBL-001 + BI2536 Sensitive : D	ABSK091 + NBL-001 + BI2536 Sensitive: D – Preclinical ABSK091 + NBL-001 + BI2536 Sensitive : D
FGFR1 overexpression	Breast Cancer	FGFR1 overexpression	Breast Cancer	palbociclib + ABSK091 Sensitive: D – Preclinical palbociclib + ABSK091 Sensitive : D	palbociclib + ABSK091 Sensitive: D – Preclinical palbociclib + ABSK091 Sensitive : D
CDH2 overexpression + KRAS wild-type	Lung Adenocarcinoma	CDH2 overexpression + KRAS wild-type	Lung Adenocarcinoma	ABSK091 Sensitive: D – Preclinical ABSK091 Sensitive : D	ABSK091 Sensitive: D – Preclinical ABSK091 Sensitive : D
MET expression	Ovarian Cancer	MET expression	Ovarian Cancer	ABSK091 Sensitive: D – Preclinical ABSK091 Sensitive : D	ABSK091 Sensitive: D – Preclinical ABSK091 Sensitive : D
FGF19 expression	Ovarian Cancer	FGF19 expression	Ovarian Cancer	ABSK091 Sensitive: D – Preclinical ABSK091 Sensitive : D	ABSK091 Sensitive: D – Preclinical ABSK091 Sensitive : D

fexagratinib (ABSK091)

Associations
(32)

Associations
(32)

fexagratinib (ABSK091)

Associations(32)

Associations(32)

Associations
(32)

Associations
(32)